Patents Examined by Catherine S Hibbert
  • Patent number: 11225659
    Abstract: The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13e or Cas13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 18, 2022
    Assignee: HuiGene Therapeutics Co., Ltd.
    Inventors: Hui Yang, Chunlong Xu, Yingsi Zhou, Qingquan Xiao
  • Patent number: 11220676
    Abstract: Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: January 11, 2022
    Inventors: Michael Wacker, Michael Kowarik, Fabiana Fernandez
  • Patent number: 11192929
    Abstract: Materials and methods for using modified Cas9-APOBEC fusion polypeptides for targeted modification of specific DNA sequences are provided herein.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 7, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Reuben S. Harris, Hideki Aihara
  • Patent number: 11179480
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 23, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins
  • Patent number: 11180544
    Abstract: A method of producing an antibody fragment for a target antigen includes administering an immunizing mixture containing the target antigen to a cartilaginous fish for at least two times; collecting a blood sample from the cartilaginous fish; extracting RNAs from the blood sample; subjecting said RNAs to reverse transcription to obtain a complementary DNA, and optionally amplifying the cDNA to obtain a mixture of amplified cDNAs followed by purification. Also covered are methods of producing an antibody fragment from a shark; antibody fragments obtained from the method; a kit comprising antibody fragments; and methods of determining the presence and/or amount of a target antigen in a sample.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: November 23, 2021
    Assignee: City University of Hong Kong
    Inventors: Jiahai Shi, Lai Leo Chan, Likun Wei, Limin Feng
  • Patent number: 11155814
    Abstract: Methods for gene editing and predicting non-random editing events are described. The methods use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems to characterize and manipulate DNA repair outcomes at Cas-initiated double-strand breaks (DSBs) to anticipate functional outcomes.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 26, 2021
    Assignee: Caribou Biosciences, Inc.
    Inventors: Daniel Capurso, Andrew P. May, Megan Van Overbeek
  • Patent number: 11125739
    Abstract: Gene editing can be performed by introducing gene-editing components into a cell by mechanical cell disruption. Related apparatus, systems, techniques, and articles are also described. The methods and systems of the invention solve the problem of intracellular delivery of gene editing components and gene editing complexes to target cells. The results described herein indicate that delivery of gene editing components, e.g., protein, ribonucleic acid (RNA), and deoxyribonucleic acid (DNA), by mechanical disruption of cell membranes leads to successful gene editing. Because intracellular delivery of gene editing materials is a current challenge, the methods provide a robust mechanism to engineer target cells without the use of potentially harmful viral vectors or electric fields.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 21, 2021
    Assignees: Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Armon R. Sharei, Marc Lajoie, Klavs F. Jensen, Robert S. Langer
  • Patent number: 11124847
    Abstract: A method for generating a reporter cell line comprises culturing a cell line capable of undergoing two or more consecutive stages of differentiation and performing the targeted insertion of two or more secretable reporter genes into the genome of the cultured cell line to form edited cells. One or more first stage inserted secretable reporter genes are placed under control of promoters for genes canonically expressed during the first stage of differentiation, and one or more second stage inserted secretable reporter genes are placed under control of promoters for genes canonically expressed during the second stage of differentiation but not during the first stage of differentiation. Differentiation of the clonally expanded edited cells is then induced to the first stage of differentiation, thus inducing expression of the first stage inserted secretable reporter genes.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 21, 2021
    Assignee: NZUMBE, INC.
    Inventors: James M. Stafford, Michael R. Rountree
  • Patent number: 11116827
    Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus.
    Type: Grant
    Filed: June 2, 2018
    Date of Patent: September 14, 2021
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Joseph Balint, Elizabeth Gabitzsch
  • Patent number: 11111492
    Abstract: Described herein are methods and compositions for rapid and precise genome editing at any desired genomic position in almost all cells and organisms. The methods utilize a cytosine-specific Cas9 endonuclease and are suitable for applications requiring targeting cytosine adjacent DNA. The methods generally include introducing a cytosine-specific Cas9 endonuclease, a single guide RNA, and optionally a DNA repair template that is utilized in either non-homologous end joining or homology directed repair. The methods can be used to effect gene knockout, gene knockdown, gene substitution, or gene introduction in cells and organisms.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 7, 2021
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Hong Li, Martin Tsui, Travis Hand
  • Patent number: 11111504
    Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: September 7, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Susannah Brydges, Jose F. Rojas, Gregg S. Warshaw, Chia-Jen Siao
  • Patent number: 11098310
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 24, 2021
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11091524
    Abstract: Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 17, 2021
    Inventor: Paul L. Hermonat
  • Patent number: 11065311
    Abstract: This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: July 20, 2021
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Christopher R. Logg, Noriyuki Kasahara
  • Patent number: 11060139
    Abstract: Provided herein are methods and compositions for the sequencing of long nucleic acids, such as DNA. The methods and compositions are suited for the spatial labeling and sequencing of long nucleic acid molecules.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: July 13, 2021
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Glenn McGall, Justin Costa, Wei Zhou
  • Patent number: 11060153
    Abstract: The present invention provides systems and methods for performing forward genetic screens in cells and methods of treating disease through inhibiting targets identified in a forward genetic screen as involved in a pathway associated with the disease. The invention involves the use of multiple tandem fluorescent reporter molecules separated by cleavage sites under the control of a single promoter to enhance the fluorescent readout from a cell screen.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 13, 2021
    Assignee: Yale University
    Inventors: Andrei Alexandrov, Joan Steitz
  • Patent number: 11060110
    Abstract: The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: July 13, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Janice J. Chou
  • Patent number: 11046963
    Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to methods of increasing the expression level of a protein of interest of a bacterial host cell in a production process. The invention relates particularly to improving the capacity of a bacterial host cell to express a protein of interest by expressing a phage protein during the production process which inhibits growth of the bacterial host cell. Decoupling growth of the bacterial host cell of manufacturing of the protein of interest during the production process reduces (i) the metabolic burden, (ii) oxygen demand, (iii) metabolic heat development, and (iv) avoids stress response caused by heterologous protein expression and thereby increases the capacity of a host cell to produce the protein of interest.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 29, 2021
    Assignee: enGenes Biotech GmbH
    Inventors: Juergen Mairhofer, Gerald Striedner, Reingard Grabherr, Monika Wilde
  • Patent number: 11028410
    Abstract: A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 8, 2021
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 10988519
    Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 27, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Damodar Gullipalli, Takashi Miwa